179 related articles for article (PubMed ID: 30275211)
21. Clinical impact of skeletal muscle mass change during the neoadjuvant chemotherapy period in patients with gastric cancer: An ancillary study of JCOG1002.
Sato R; Tokunaga M; Mizusawa J; Sato Y; Ito S; Takahari D; Sano T; Onaya H; Yoshikawa T; Boku N; Terashima M
World J Surg; 2024 Jan; 48(1):163-174. PubMed ID: 38686798
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of intraperitoneal and intravenous chemotherapy for advanced gastric cancer with peritoneal metastasis.
Chen Y; Wang XJ; Lin RB; Chen L; Lin G; Guo ZQ
Tumori; 2014; 100(5):e180-8. PubMed ID: 25343556
[TBL] [Abstract][Full Text] [Related]
23. Improving trends in survival of patients who receive chemotherapy for metastatic or recurrent gastric cancer: 12 years of experience at a single institution.
Koo DH; Ryu MH; Ryoo BY; Seo J; Lee MY; Chang HM; Lee JL; Lee SS; Kim TW; Kang YK
Gastric Cancer; 2015 Apr; 18(2):346-53. PubMed ID: 24832201
[TBL] [Abstract][Full Text] [Related]
24. Post progression survival analysis of metastatic gastric and gastroesophageal junction cancer patients after second-line treatment.
Turkmen E; Erdogan B; Kodaz H; Hacibekiroglu I; Onal Y; Uzunoglu S; Kilic N; Cicin I
Acta Gastroenterol Belg; 2016; 79(2):211-5. PubMed ID: 27382940
[TBL] [Abstract][Full Text] [Related]
25. Loss of skeletal muscle mass during palliative chemotherapy is a poor prognostic factor in patients with advanced gastric cancer.
Park SE; Choi JH; Park JY; Kim BJ; Kim JG; Kim JW; Park JM; Chi KC; Hwang IG
Sci Rep; 2020 Oct; 10(1):17683. PubMed ID: 33077864
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of cisplatin, epirubicin, UFT, and leucovorin (PELUF) as first-line chemotherapy in metastatic gastric cancer.
Idelevich E; Karminsky N; Dinerman M; Katsenelson RL; Zvi NB; Baruch NB; Biran H; Man S; Shani A
Acta Oncol; 2007; 46(3):324-9. PubMed ID: 17450467
[TBL] [Abstract][Full Text] [Related]
27. Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
Cui Y; Li Q; Yu Y; Chen Y; Feng Y; Wang Y; Liu T
Cancer Chemother Pharmacol; 2013 Jan; 71(1):145-52. PubMed ID: 23064955
[TBL] [Abstract][Full Text] [Related]
28. Loss of skeletal muscle mass during neoadjuvant treatments correlates with worse prognosis in esophageal cancer: a retrospective cohort study.
Järvinen T; Ilonen I; Kauppi J; Salo J; Räsänen J
World J Surg Oncol; 2018 Feb; 16(1):27. PubMed ID: 29433514
[TBL] [Abstract][Full Text] [Related]
29. Skeletal muscle loss after total gastrectomy, exacerbated by adjuvant chemotherapy.
Yamaoka Y; Fujitani K; Tsujinaka T; Yamamoto K; Hirao M; Sekimoto M
Gastric Cancer; 2015 Apr; 18(2):382-9. PubMed ID: 24715254
[TBL] [Abstract][Full Text] [Related]
30. The relationship between platelet-lymphocyte ratio, neutrophil-lymphocyte ratio, and survival in metastatic gastric cancer on firstline modified docetaxel and cisplatinum plus 5 Fluorourasil Regimen: A single institute experience.
Dogan M; Eren T; Ozdemir N; Cigirgan CL; Zengin N
Saudi J Gastroenterol; 2015; 21(5):320-4. PubMed ID: 26458860
[TBL] [Abstract][Full Text] [Related]
31. Predictive and prognostic value of serum AFP level and its dynamic changes in advanced gastric cancer patients with elevated serum AFP.
Wang YK; Shen L; Jiao X; Zhang XT
World J Gastroenterol; 2018 Jan; 24(2):266-273. PubMed ID: 29375212
[TBL] [Abstract][Full Text] [Related]
32. Sarcopenia as a predictor of survival and chemotoxicity in patients with epithelial ovarian cancer receiving platinum and taxane-based chemotherapy.
Staley SA; Tucker K; Newton M; Ertel M; Oldan J; Doherty I; West L; Zhang Y; Gehrig PA
Gynecol Oncol; 2020 Mar; 156(3):695-700. PubMed ID: 31928805
[TBL] [Abstract][Full Text] [Related]
33. Skeletal muscle loss during chemotherapy and its association with survival and systemic treatment toxicity in metastatic colorectal cancer: An AGEO prospective multicenter study.
Gallois C; Bourillon C; Auclin E; Artru P; Lièvre A; Lecomte T; Locher C; Marthey L; Faroux R; Pernot S; Barret M; Taieb J
Clin Res Hepatol Gastroenterol; 2021 Nov; 45(6):101603. PubMed ID: 33662782
[TBL] [Abstract][Full Text] [Related]
34. Skeletal Muscle Attenuation (Sarcopenia) Predicts Reduced Overall Survival in Patients with Advanced Epithelial Ovarian Cancer Undergoing Primary Debulking Surgery.
Ataseven B; Luengo TG; du Bois A; Waltering KU; Traut A; Heitz F; Alesina PF; Prader S; Meier B; Schneider S; Koch JA; Walz M; Groeben HT; Nina P; Brunkhorst V; Heikaus S; Harter P
Ann Surg Oncol; 2018 Oct; 25(11):3372-3379. PubMed ID: 30069659
[TBL] [Abstract][Full Text] [Related]
35. Potential of extravasated platelet aggregation as a surrogate marker for overall survival in patients with advanced gastric cancer treated with preoperative docetaxel, cisplatin and S-1: a retrospective observational study.
Saito H; Fushida S; Miyashita T; Oyama K; Yamaguchi T; Tsukada T; Kinoshita J; Tajima H; Ninomiya I; Ohta T
BMC Cancer; 2017 Apr; 17(1):294. PubMed ID: 28449652
[TBL] [Abstract][Full Text] [Related]
36. Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy.
Giampieri R; Maccaroni E; Mandolesi A; Del Prete M; Andrikou K; Faloppi L; Bittoni A; Bianconi M; Scarpelli M; Bracci R; Scartozzi M; Cascinu S
Gastric Cancer; 2017 Jan; 20(1):156-163. PubMed ID: 26796888
[TBL] [Abstract][Full Text] [Related]
37. Splenic hilar lymph node metastasis independently predicts poor survival for patients with gastric cancers in the upper and/or the middle third of the stomach.
Zhu GL; Sun Z; Wang ZN; Xu YY; Huang BJ; Xu Y; Zhu Z; Xu HM
J Surg Oncol; 2012 Jun; 105(8):786-92. PubMed ID: 22105768
[TBL] [Abstract][Full Text] [Related]
38. Sarcopenia is a Negative Prognostic Factor After Curative Resection of Colorectal Cancer.
Miyamoto Y; Baba Y; Sakamoto Y; Ohuchi M; Tokunaga R; Kurashige J; Hiyoshi Y; Iwagami S; Yoshida N; Yoshida M; Watanabe M; Baba H
Ann Surg Oncol; 2015 Aug; 22(8):2663-8. PubMed ID: 25564158
[TBL] [Abstract][Full Text] [Related]
39. Survival of gastric cancer with concomitant liver metastases.
Kwok CM; Wu CW; Lo SS; Shen KH; Hsieh MC; Lui WY
Hepatogastroenterology; 2004; 51(59):1527-30. PubMed ID: 15362793
[TBL] [Abstract][Full Text] [Related]
40. Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer.
Daly LE; Ní Bhuachalla ÉB; Power DG; Cushen SJ; James K; Ryan AM
J Cachexia Sarcopenia Muscle; 2018 Apr; 9(2):315-325. PubMed ID: 29318756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]